December 11, 2018
Otsuka Pharmaceutical Co., Ltd.
Otsuka subsidiary Avanir and Optinose agree to terminate license agreement
for migraine treatment ONZETRA®Xsail®
Otsuka Pharmaceutical Co., Ltd. today announces that its U.S.-based indirect subsidiary Avanir Pharmaceuticals, Inc. has agreed with Optinose, Inc. to return to Optinose the rights in North America to ONZETRA®Xsail® for the acute treatment of migraines in adults.
Avanir comprehensively reevaluated the U.S. migraine medication market. As a result, the decision was made to terminate the licensing agreement.
Information in this news release was current as of the original release date.